AN2 Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANTX research report →
Companywww.an2therapeutics.com
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease.
- CEO
- Eric E. Easom
- IPO
- 2022
- Employees
- 22
- HQ
- Menlo Park, CA, US
Price Chart
Valuation
- Market Cap
- $125.78M
- P/E
- -4.52
- P/S
- 0.00
- P/B
- 1.91
- EV/EBITDA
- -1.98
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -52.35%
- ROIC
- -45.31%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-35,174,000 · 31.46%
- EPS
- $-1.16 · 32.56%
- Op Income
- $-38,109,000
- FCF YoY
- 39.43%
Performance & Tape
- 52W High
- $6.91
- 52W Low
- $1.00
- 50D MA
- $4.12
- 200D MA
- $1.93
- Beta
- -0.96
- Avg Volume
- 1.48M
Get TickerSpark's AI analysis on ANTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 10, 26 | Aziz Kabeer | other | 3,775 |
| Apr 10, 26 | Marks Gilbert Lynn | other | 3,775 |
| Apr 10, 26 | Martin Patricia A. | other | 1,192 |
| Mar 19, 26 | Day Lucy | other | 82,300 |
| Mar 19, 26 | Day Lucy | other | 73,665 |
| Mar 19, 26 | Day Lucy | other | 66,000 |
| Mar 19, 26 | Day Lucy | sell | 82,300 |
| Mar 19, 26 | Day Lucy | sell | 73,665 |
| Mar 19, 26 | Day Lucy | sell | 66,000 |
| Mar 19, 26 | Chanda Sanjay | other | 66,000 |
Our ANTX Coverage
We haven't published any research on ANTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANTX Report →